Skip to main navigation
Loading
  • News
  • Investors
  • Careers
  • Contact
  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
  • Our Approach
    • What We Do
    • Partnering
  • Patients & Providers
    • Niemann-Pick Disease Type C
    • Sleep Disorders
    • Expanded Access Policy
  • Science & Pipeline
    • Pipeline
    • Clinical Trials
    • Products
    • Publications & Presentations
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Information
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home
  • Menu Menu

SEC Filings

  • Overview
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Analyst Coverage
  • Press Releases
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Committee Composition
    • IRS – Required Disclosures
  • SEC Filings
    • Quarterly Results
  • Contact
  • Email Alerts
Filing date Form Description Filing Group View
03-13-2023 4

Statement of changes in beneficial ownership of securities

3,4,5
0001437749-23-006276.rtf
0001437749-23-006276.xls
0001437749-23-006276.pdf
View HTML
03-13-2023 4

Statement of changes in beneficial ownership of securities

3,4,5
0001437749-23-006277.rtf
0001437749-23-006277.xls
0001437749-23-006277.pdf
View HTML
03-13-2023 4

Statement of changes in beneficial ownership of securities

3,4,5
0001437749-23-006278.rtf
0001437749-23-006278.xls
0001437749-23-006278.pdf
View HTML
03-13-2023 4

Statement of changes in beneficial ownership of securities

3,4,5
0001437749-23-006280.rtf
0001437749-23-006280.xls
0001437749-23-006280.pdf
View HTML
03-13-2023 PRER14A

Proxy soliciting materials. Revised preliminary material

Proxy Filings
0001437749-23-006372.rtf
0001437749-23-006372.xls
0001437749-23-006372.pdf
View HTML
03-07-2023 8-K

Report of unscheduled material events or corporate event

Current Reports
0001437749-23-005593.rtf
0001437749-23-005593.xls
0001437749-23-005593.pdf
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
03-07-2023 DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
0001437749-23-005681.rtf
0001437749-23-005681.xls
0001437749-23-005681.pdf
View HTML
03-07-2023 S-8

Securities offered to employees pursuant to employee benefit plans

Registration Statements
0001437749-23-005706.rtf
0001437749-23-005706.xls
0001437749-23-005706.pdf
View HTML
03-07-2023 10-K

Annual report which provides a comprehensive overview of the company for the past year

Annual Filings
0001437749-23-005703.rtf
0001437749-23-005703.xls
0001437749-23-005703.pdf
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
03-07-2023 S-8

Securities offered to employees pursuant to employee benefit plans

Registration Statements
0001437749-23-005708.rtf
0001437749-23-005708.xls
0001437749-23-005708.pdf
View HTML
Pagination
  • First page «
  • Previous page ‹
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • …
  • Next page ›
  • Last page »

Data provided by Kaleidoscope.

  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
  • Our Approach
    • What We Do
    • Partnering
  • Patients & Providers
    • Niemann-Pick Disease Type C
    • Sleep Disorders
    • Expanded Access Policy
  • Science & Pipeline
    • Pipeline
    • Clinical Trials
    • Products
    • Publications & Presentations
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Information
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home

© 2023 Zevra Therapeutics, Inc. All rights reserved. Privacy Policy | Terms of Use

Scroll to top